Context Therapeutics Stock Book Value Per Share

CNTX Stock  USD 1.02  0.07  6.42%   
Context Therapeutics fundamentals help investors to digest information that contributes to Context Therapeutics' financial success or failures. It also enables traders to predict the movement of Context Stock. The fundamental analysis module provides a way to measure Context Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Context Therapeutics stock.
Last ReportedProjected for Next Year
Book Value Per Share 0.74  0.78 
Tangible Book Value Per Share 0.74  0.78 
Book Value Per Share is likely to rise to 0.78 in 2024. Tangible Book Value Per Share is likely to rise to 0.78 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Context Therapeutics Company Book Value Per Share Analysis

Context Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

 = 

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Context Therapeutics Book Value Per Share

    
  0.74 X  
Most of Context Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Context Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Context Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Context Therapeutics is extremely important. It helps to project a fair market value of Context Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Context Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Context Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Context Therapeutics' interrelated accounts and indicators.
0.98-0.07-0.51-0.390.040.08-0.690.32-0.550.97-0.60.080.57-0.02-0.320.460.260.33
0.980.06-0.54-0.440.04-0.06-0.830.27-0.610.97-0.73-0.060.710.0-0.440.550.410.44
-0.070.060.48-0.02-0.76-0.6-0.33-0.880.380.14-0.03-0.60.5-0.7-0.880.760.890.88
-0.51-0.540.480.31-0.590.180.45-0.770.7-0.390.620.18-0.32-0.56-0.360.250.180.35
-0.39-0.44-0.020.31-0.32-0.010.44-0.260.28-0.370.35-0.01-0.41-0.370.2-0.42-0.17-0.22
0.040.04-0.76-0.59-0.320.36-0.080.91-0.64-0.17-0.360.36-0.070.990.61-0.46-0.58-0.6
0.08-0.06-0.60.18-0.010.360.270.39-0.11-0.080.211.0-0.320.270.35-0.25-0.49-0.35
-0.69-0.83-0.330.450.44-0.080.27-0.120.68-0.70.90.27-0.94-0.070.62-0.64-0.67-0.62
0.320.27-0.88-0.77-0.260.910.39-0.12-0.710.1-0.40.39-0.070.860.66-0.5-0.63-0.66
-0.55-0.610.380.70.28-0.64-0.110.68-0.71-0.410.91-0.11-0.44-0.61-0.050.040.060.05
0.970.970.14-0.39-0.37-0.17-0.08-0.70.1-0.41-0.56-0.080.61-0.2-0.490.60.420.5
-0.6-0.73-0.030.620.35-0.360.210.9-0.40.91-0.560.21-0.72-0.360.32-0.3-0.34-0.32
0.08-0.06-0.60.18-0.010.361.00.270.39-0.11-0.080.21-0.320.270.35-0.25-0.49-0.35
0.570.710.5-0.32-0.41-0.07-0.32-0.94-0.07-0.440.61-0.72-0.32-0.08-0.70.730.820.7
-0.020.0-0.7-0.56-0.370.990.27-0.070.86-0.61-0.2-0.360.27-0.080.57-0.43-0.55-0.57
-0.32-0.44-0.88-0.360.20.610.350.620.66-0.05-0.490.320.35-0.70.57-0.94-0.92-1.0
0.460.550.760.25-0.42-0.46-0.25-0.64-0.50.040.6-0.3-0.250.73-0.43-0.940.860.95
0.260.410.890.18-0.17-0.58-0.49-0.67-0.630.060.42-0.34-0.490.82-0.55-0.920.860.92
0.330.440.880.35-0.22-0.6-0.35-0.62-0.660.050.5-0.32-0.350.7-0.57-1.00.950.92
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition

Context Common Stock Shares Outstanding

Common Stock Shares Outstanding

15.36 Million

At this time, Context Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year.
In accordance with the recently published financial statements, the book value per share of Context Therapeutics is about 0.744 times. This is 143.76% lower than that of the Pharmaceuticals sector and 100.3% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.96% higher than that of the company.

Context Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Context Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics of similar companies.
Context Therapeutics is currently under evaluation in book value per share category among its peers.

Context Fundamentals

About Context Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Context Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.